Earlier this week, Elon Musk announced his brain-computer interface company, Neuralink, had implanted a device in a human for the first time. The company’s PRIME study, approved by the US Food and Drug Administration last year, is testing a brain implant for “people with paralysis to control external devices with their thoughts”.
In the past few years, Neuralink has faced investigation for mistreatment of lab animals and seen the departure of several company executives. Nevertheless, the PRIME trial is a significant milestone for a company less than ten years old.
However, Neuralink’s challenges are far from over. Implanting a device is just the beginning of a decades-long clinical project beset with competitors, financial hurdles and ethical quandaries.
Decades of development
The first reported demonstration of a brain-computer interface occurred in 1963. During a lecture at the University of Oxford, neuroscientist William Grey Walter bewildered his audience by linking one of his patient’s brains to the projector, where they advanced the slides of his presentation using only their thoughts.
However, the current wave of exploration in using brain-recording techniques to restore movement and communication to patients with severe paralysis began in the early 2000s. It draws on studies from the 1940s which measured the activity of single neurons, and more complex experiments on rats and monkeys in the 1990s.
Neuralink’s technology belongs to the next generation of recording devices. These have multiple electrodes, greater precision, and are safer, longer-lasting, and more compatible with the body. The Neuralink implant is thinner, smaller and less obtrusive than the “Utah array” device, widely used in existing brain-computer interfaces, which has been available since 2005.
Neuralink’s device is implanted by a special robot which rapidly inserts polymer threads, each containing dozens of electrodes. In total, the device has 3,072 electrodes – dwarfing the 100 electrodes of the Utah array.
Competitors
Neuralink faces stiff competition in the race to commercialise the first next-generation brain-computer interface.
Arguably its most fierce competitor is an Australian company called Synchron. This Melbourne-based start-up recently used a microelectrode mesh threaded through the blood vessels of the brain. This allowed paralysed patients to use tablets and smartphones, surf the internet, send emails, manage finances (and post on X, formerly Twitter).
The Synchron implant is described as a “minimally invasive” brain-computer interface. It requires only a minor incision in the neck, rather than the elaborate neurosurgery required by Neuralink and most other brain-computer interfaces.
In 2021, Synchron received a “Breakthrough Device Designation” in the United States, and is now onto its third clinical trial.
Patient welfare
This competitive landscape raises potential ethical issues concerning the welfare of patients in the PRIME study. For one, it is notoriously difficult to recruit participants to neural implant studies. Patients must meet strict criteria to be eligible, and the trials are inherently risky and ask a lot of participants.
Musk’s public profile may help Neuralink find and enrol suitable patients. However, the company will need to be prepared to provide long-term support (potentially decades) to patients. If things go wrong, patients may need support to live with the consequences; if things go right, Neuralink may need to make sure the devices don’t stop working.
In 2022, a company called Second Sight Medical Product demonstrated the risks. Second Sight made retinal implants to treat blindness. When the company went bankrupt, it left more than 350 patients around the world with obsolete implants and no way to remove them.
If Neuralink’s devices are successful, they are likely to transform patients’ lives. What happens if the company winds up operations because it can’t make a profit? A plan for long-term care is essential.
What’s more, the considerable hype surrounding Neuralink may have implications for obtaining informed consent from potential participants.
Musk famously compared the implant to a “Fitbit in your skull”. The device itself, Musk recently revealed, is misleadingly named “Telepathy”.
This techno-futurist language may give participants unrealistic expectations about the likelihood and kind of individual benefit. They may also underappreciate the risks, which could include severe brain damage.
The way forward
In this next chapter of the Neuralink odyssey, Musk and his team must maintain a strong commitment to research integrity and patient care. Neuralink’s establishment of a patient registry to connect with patient communities is a step in the right direction.
Long-term planning and careful use of language will be necessary to preventing harm to patients and families.
The nightmare scenario for all neurotechnology research would be a repeat of Walter Freeman’s disastrous pre-frontal lobotomy experiments in the 1940s and 1950s. These had catastrophic consequences for patients and set research back by generations.
Q&As Insights
What is the objective of Neuralink’s PRIME study?
The PRIME study is intended to assess a brain implant for patients with paralysis, allowing them to control external devices with their minds.
What is the difference between Neuralink’s technology and the brain-computer interfaces which were the last in this field?
The neuralink technology is representative of the next generation with more electrodes, higher accuracy, security, life span and compatibility. It measures 0.7 mm in thickness and 5 mm in diameter which is much thinner and less obtrusive than existing devices, 3,072 electrodes compared to the 100 in the widely used Utah array.
What companies can be considered Neuralink’s primary rivals in the field of the brain-computer interface market?
Synchron is one of Neuralink’s rivals – an Australian manufacturer. Its popularity as a minimally invasive approach via a microelectrode mesh through blood vessels presents stiff competition in the next generation of brain-computer interfaces.
Ethically, what issues would arise with respect to the wellbeing of patients in Neuralink’s PRIME study.
The competitive market leads to ethical issues in terms of patient care especially in the recruitment of participants for neural implant studies. Strict eligibility criteria, control of inherent risks, and long-term support of participants are needed.
What will Neuralink do about long-term care and patient expectations when they arise?
Notably, Neuralink understands the need for long-term planning and patient management. Creation of a patient registry for the connectivity to communities is a good move. Initially, language use should be clear and managing expectations will help avoid harm to patients and families.
Except for the Q&As Insights, This report is given by The Conversation. The Sen Times holds no responsibility for its content.